文献速递心律失常血脂与心血管预防

心房颤动患者联用口服抗凝药与非甾体抗炎药的治疗分析

Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation.
PubMed 文献 · J Am Coll Cardiol · 2018-07-09

该研究为RE-LY试验的事后分析,评估房颤患者使用NSAIDs对临床结局的影响。在18,113例患者中,2,279例至少使用过一次NSAIDs。结果显示,NSAIDs使用显著增加大出血、胃肠大出血、卒中或体循环栓塞及住院风险,但未改变达比加群酯150mg或110mg每日两次相对于华法林的安全性和疗效。

要点

  • 房颤患者使用NSAIDs显著增加大出血风险(HR 1.68)。
  • NSAIDs使用增加卒中/体循环栓塞风险(HR 1.50)。
  • 达比加群酯与华法林的相对安全性和疗效未受NSAIDs影响。

核心结论

  • NSAIDs使用与房颤患者大出血、卒中/体循环栓塞和住院风险增加相关。
  • 达比加群酯150mg和110mg每日两次相对于华法林的安全性和疗效未因NSAIDs使用而改变。

研究设计与样本

  • RE-LY试验的事后分析,共纳入18,113例房颤患者,其中2,279例至少使用过一次NSAIDs。
  • 采用治疗无关的多变量校正Cox回归分析比较NSAIDs使用与未使用的临床结局,并进行交互分析和时变协变量分析。

主要发现

  • NSAIDs使用使大出血风险显著升高(HR 1.68;95%CI 1.40-2.02;p<0.0001)。
  • NSAIDs使用使胃肠大出血风险显著升高(HR 1.81;95%CI 1.35-2.43;p<0.0001)。
  • NSAIDs使用使卒中/体循环栓塞风险显著升高(HR 1.50;95%CI 1.12-2.01;p=0.007)。
  • NSAIDs使用与心肌梗死风险无显著关联(HR 1.22;95%CI 0.77-1.93;p=0.40)。
  • NSAIDs使用使住院风险显著升高(HR 1.64;95%CI 1.51-1.77;p<0.0001)。

关键数值与推荐

  • 达比加群酯150mg每日两次与华法林相比,NSAIDs使用对大出血风险的交互作用p=0.63。
  • 达比加群酯110mg每日两次与华法林相比,NSAIDs使用对大出血风险的交互作用p=0.93。
  • 达比加群酯150mg每日两次与华法林相比,NSAIDs使用对卒中/体循环栓塞风险的交互作用p=0.59。
  • 达比加群酯110mg每日两次与华法林相比,NSAIDs使用对卒中/体循环栓塞风险的交互作用p=0.54。

临床怎么用

  • 房颤患者接受口服抗凝治疗时应谨慎评估NSAIDs的使用,因其增加出血和血栓栓塞风险。
  • 使用达比加群酯或华法林时,联用NSAIDs的风险增加相似,无需仅因NSAIDs使用而改变抗凝药选择。

局限性

  • 本研究为RE-LY试验的事后分析,可能存在残余混杂。
  • NSAIDs使用为时间依赖性变量,但未区分具体药物、剂量和疗程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used medications that can potentially increase the risk of bleeding and thrombosis. OBJECTIVES: This study quantified the effect of NSAIDs in the RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) trial. METHODS: This was a post hoc analysis of NSAIDs in the RE-LY study, which compared dabigatran etexilate (DE) 150 and 110 mg twice daily (b.i.d.) with warfarin in patients with atrial fibrillation. Treatment-independent, multivariate-adjusted Cox regression analysis assessed clinical outcomes by comparing NSAID use with no NSAID use. Interaction analysis was obtained from treatment-dependent Cox regression modeling. Time-varying covariate analysis for NSAID use was applied to the Cox model. RESULTS: Among 18,113 patients in the RE-LY study, 2,279 patients used NSAIDs at least once during the trial. Major bleeding was significantly elevated with NSAID use (hazard ratio [HR]: 1.68; 95% confidence interval [CI]: 1.40 to 2.02; p < 0.0001). NSAID use did not significantly alter the risk of major bleeding for DE 150 or 110 mg b.i.d. relative to warfarin (pinteraction = 0.63 and 0.93, respectively). Gastrointestinal major bleeding was significantly elevated with NSAID use (HR: 1.81; 95% CI: 1.35 to 2.43; p < 0.0001). The rate of stroke or systemic embolism (stroke/SE) with NSAID use was significantly elevated (HR: 1.50; 95% CI: 1.12 to 2.01; p = 0.007). The use of NSAIDs did not significantly alter the relative efficacy on stroke/SE for DE 150 or 110 mg b.i.d. relative to warfarin (pinteraction = 0.59 and 0.54, respectively). Myocardial infarction rates were similar with NSAID use compared with no NSAID use (HR: 1.22; 95% CI: 0.77 to 1.93; p = 0.40). Patients were more frequently hospitalized if they used an NSAID (HR: 1.64; 95% CI: 1.51 to 1.77; p < 0.0001). CONCLUSIONS: The use of NSAIDs was associated with increased risk of major bleeding, stroke/SE, and hospitalization. The safety and efficacy of DE 150 and 110 mg b.i.d. relative to warfarin were not altered. (Randomized Evaluation of Long Term Anticoagulant Therapy [RE-LY]; NCT00262600).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Kent AP, Brueckmann M, Fraessdorf M, et al. Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018. PMID: 30012318. doi:10.1016/j.jacc.2018.04.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。